KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Cash from Financing Activities (2016 - 2025)

Historic Cash from Financing Activities for Halozyme Therapeutics (HALO) over the last 16 years, with Q4 2025 value amounting to $239.5 million.

  • Halozyme Therapeutics' Cash from Financing Activities rose 19719.98% to $239.5 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$85.2 million, marking a year-over-year increase of 6108.31%. This contributed to the annual value of -$85.2 million for FY2025, which is 6108.31% up from last year.
  • According to the latest figures from Q4 2025, Halozyme Therapeutics' Cash from Financing Activities is $239.5 million, which was up 19719.98% from -$22.4 million recorded in Q3 2025.
  • Halozyme Therapeutics' Cash from Financing Activities' 5-year high stood at $367.8 million during Q2 2022, with a 5-year trough of -$299.0 million in Q2 2025.
  • In the last 5 years, Halozyme Therapeutics' Cash from Financing Activities had a median value of -$1.9 million in 2024 and averaged -$13.6 million.
  • Its Cash from Financing Activities has fluctuated over the past 5 years, first skyrocketed by 92181.11% in 2022, then tumbled by 2648044.87% in 2023.
  • Quarter analysis of 5 years shows Halozyme Therapeutics' Cash from Financing Activities stood at -$156.0 million in 2021, then surged by 104.06% to $6.3 million in 2022, then tumbled by 4048.81% to -$249.9 million in 2023, then rose by 1.4% to -$246.4 million in 2024, then surged by 197.2% to $239.5 million in 2025.
  • Its Cash from Financing Activities stands at $239.5 million for Q4 2025, versus -$22.4 million for Q3 2025 and -$299.0 million for Q2 2025.